Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort
Rachel Jaber Chehayeb, Jaiveer Singh, Carlos Matute-Martinez, Nathan W. Chen, Ana Ferrigno Guajardo, Derrick Lin, Ritujith Jayakrishnan, Anthos Christofides, Etienne Leveille, Yunju Im, Giulia Biancon, Jennifer VanOudenhove, Eiman Ibrahim, Anastasias Ardasheva, Alokkumar Jha, John Hwa, Stephanie Hal · 2024
Read Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort by Rachel Jaber Chehayeb, Jaiveer Singh, Carlos Matute-Martinez, Nathan W. Chen, Ana Ferrigno Guajardo, Derrick Lin, Ritujith Jayakrishnan, Anthos Christofides, Etienne Leveille, Yunju Im, Giulia Biancon, Jennifer VanOudenhove, Eiman Ibrahim, Anastasias Ardasheva, Alokkumar Jha, John Hwa, Stephanie Hal (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11590368.txt.
Description
Rachel Jaber Chehayeb and colleagues followed cancer patients on immune therapy in 2024. Some older adults carry blood cell gene changes called CHIP. Those changes raise death and heart muscle disease risks. They also stir immune cell activation in heart failure. Whether they raise heart inflammation risk from immune drugs was unknown. The team enrolled solid tumor patients in a forward-looking study. Blood sequencing set each patient's CHIP status at entry. Heart inflammation events were tracked for years.
Half of the eighty-eight treated patients carried CHIP changes. Heart inflammation struck far more often in that half. Death also ran higher among CHIP carriers. Adjusted models doubled the risk from CHIP status alone. That matched the risk from using two immune drugs at once. Coronary calcium was the only uneven health trait. The authors urge CHIP checks before immune therapy starts. Closer heart monitoring may suit carriers, they say.
Catalog record
| CREATOR | Rachel Jaber Chehayeb, Jaiveer Singh, Carlos Matute-Martinez, Nathan W. Chen, Ana Ferrigno Guajardo, Derrick Lin, Ritujith Jayakrishnan, Anthos Christofides, Etienne Leveille, Yunju Im, Giulia Biancon, Jennifer VanOudenhove, Eiman Ibrahim, Anastasias Ardasheva, Alokkumar Jha, John Hwa, Stephanie Hal |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |